Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
Sponsor: AROG Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS1881
U.S. Govt. ID: NCT03258931
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the efficacy of crenolanib versus midostaurin (RYDAPT) in newly diagnosed acute myeloid leukemia patients with FLT3 mutations. Crenolanib is an investigational product, which means that it has not yet been approved for sale in the United States by the Food and Drug Administration (FDA).
This study is closed
Investigator
Joseph Jurcic, MD
Do You Qualify?
Are you between the age 18 years and 60 years? Yes No
Do you have Diagnosis of AML? Yes No
Do you agree to not participate in another study while on treatment for this study? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE